"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","growth_protocol_ch1","molecule_ch1","extract_protocol_ch1","extract_protocol_ch1.1","taxid_ch1","data_processing","platform_id","contact_name","contact_email","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","data_row_count","instrument_model","library_selection","library_source","library_strategy","relation","relation.1","supplementary_file_1","cell line:ch1","cell type:ch1"
"GSM2212218","MCF10controlcell","GSM2212218","Public on Sep 12 2016","Jun 23 2016","May 15 2019","SRA","1","MCF10A cells","Homo sapiens","cell line: MCF10A","cell type: normal mammary epithelial","The human mammary epithelial cell line MCF10A, and breast cancer cell lines MCF7 and MDA-MB-231 were obtained from the American Type Culture Collection (Manassas, VA). MCF10A cells were cultured in DMEM/F12 medium supplemented with 5% exosome-depleted horse serum, 20ng/ml epithelial growth factor, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10 μg/ml insulin, 100 IU/mL penicillin and 100 μg/mL streptomycin. MCF7 and MDA-MB-231 cells were cultivated in DMEM medium supplemented with 10% exosome-depleted fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Exosome-depleted FBS and horse serum were prepared by pelleting the serum exosomes by ultracentrifugation at 100,000 x g for 2 h at 4°C, and the resulting supernatant was filtered through a 0.2 μm pore filter. Cells were routinely maintained in a humidified chamber at 37°C and 5% CO2.","total RNA","Exosomes were isolated utilizing a combination of centrifugation, ultracentrifugation, and filtration as we have previously described [16] or with the Exoquick-TC reagent (System Biosciences, Mountain View, CA) following the manufacturer’s protocol. For ultracentrifugation isolation, conditioned cell culture media was collected and centrifuged at 10,000 x g for 30 min at 4°C, to remove cells and large debris. The supernatant was filtered using a 0.22-μm pore filter and the exosomes were pelleted at 100,000 x g for 1 h at 4°C. The exosome pellet was washed with 10 ml of 1X PBS and pelleted again by centrifugation at 100,000 x g for 1 h at 4°C. The resulting pellet was either suspended in 1X PBS for whole exosome applications or further processed for RNA or protein extraction. Total RNA was extracted from exosome pellet using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).","Small RNA libraries were constructed using New England Biolabs (NEB) NEBNext Multiplex Small RNA Library Prep Set for Illumina sequencers and the NEB standard protocol. Individual libraries were constructed using 1μg of total RNA isolated from each sample.","9606","Each library was indexed in order to multiplex four samples per sequencing run on the Illumina MiSeq platform using MiSeq 50 cycle Reagent Kits v2. A minimum of 17 million 50bp sequencing reads were collected from each sample and data were analyzed using Genesifter software (formerly Geospiza) (PerkinElmer, Santa Clara CA). Raw data for each sample were aligned to the most recent mirBASE database (mirBase.org [17]) with remaining reads aligned to the most recent human genome (hg18 build [18]) build in order to identify previously unknown regions that may encode for unique miRNAs. Pairwise comparison of the alignment results was done using Genesifter for identification of miRNAs that are differentially expressed at a significant level, i.e. up- or down-regulated.","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN05290413","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1873415","NONE","MCF10A","normal mammary epithelial"
"GSM2212219","MCF10controlexosome","GSM2212219","Public on Sep 12 2016","Jun 23 2016","May 15 2019","SRA","1","MCF10A cells","Homo sapiens","cell line: MCF10A","cell type: normal mammary epithelial","The human mammary epithelial cell line MCF10A, and breast cancer cell lines MCF7 and MDA-MB-231 were obtained from the American Type Culture Collection (Manassas, VA). MCF10A cells were cultured in DMEM/F12 medium supplemented with 5% exosome-depleted horse serum, 20ng/ml epithelial growth factor, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10 μg/ml insulin, 100 IU/mL penicillin and 100 μg/mL streptomycin. MCF7 and MDA-MB-231 cells were cultivated in DMEM medium supplemented with 10% exosome-depleted fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Exosome-depleted FBS and horse serum were prepared by pelleting the serum exosomes by ultracentrifugation at 100,000 x g for 2 h at 4°C, and the resulting supernatant was filtered through a 0.2 μm pore filter. Cells were routinely maintained in a humidified chamber at 37°C and 5% CO2.","total RNA","Exosomes were isolated utilizing a combination of centrifugation, ultracentrifugation, and filtration as we have previously described [16] or with the Exoquick-TC reagent (System Biosciences, Mountain View, CA) following the manufacturer’s protocol. For ultracentrifugation isolation, conditioned cell culture media was collected and centrifuged at 10,000 x g for 30 min at 4°C, to remove cells and large debris. The supernatant was filtered using a 0.22-μm pore filter and the exosomes were pelleted at 100,000 x g for 1 h at 4°C. The exosome pellet was washed with 10 ml of 1X PBS and pelleted again by centrifugation at 100,000 x g for 1 h at 4°C. The resulting pellet was either suspended in 1X PBS for whole exosome applications or further processed for RNA or protein extraction. Total RNA was extracted from exosome pellet using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).","Small RNA libraries were constructed using New England Biolabs (NEB) NEBNext Multiplex Small RNA Library Prep Set for Illumina sequencers and the NEB standard protocol. Individual libraries were constructed using 1μg of total RNA isolated from each sample.","9606","Each library was indexed in order to multiplex four samples per sequencing run on the Illumina MiSeq platform using MiSeq 50 cycle Reagent Kits v2. A minimum of 17 million 50bp sequencing reads were collected from each sample and data were analyzed using Genesifter software (formerly Geospiza) (PerkinElmer, Santa Clara CA). Raw data for each sample were aligned to the most recent mirBASE database (mirBase.org [17]) with remaining reads aligned to the most recent human genome (hg18 build [18]) build in order to identify previously unknown regions that may encode for unique miRNAs. Pairwise comparison of the alignment results was done using Genesifter for identification of miRNAs that are differentially expressed at a significant level, i.e. up- or down-regulated.","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN05290412","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1873416","NONE","MCF10A","normal mammary epithelial"
"GSM2212220","MCF7controlcell","GSM2212220","Public on Sep 12 2016","Jun 23 2016","May 15 2019","SRA","1","MCF7 breast cancer cells","Homo sapiens","cell line: MCF7","cell type: breast cancer","The human mammary epithelial cell line MCF10A, and breast cancer cell lines MCF7 and MDA-MB-231 were obtained from the American Type Culture Collection (Manassas, VA). MCF10A cells were cultured in DMEM/F12 medium supplemented with 5% exosome-depleted horse serum, 20ng/ml epithelial growth factor, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10 μg/ml insulin, 100 IU/mL penicillin and 100 μg/mL streptomycin. MCF7 and MDA-MB-231 cells were cultivated in DMEM medium supplemented with 10% exosome-depleted fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Exosome-depleted FBS and horse serum were prepared by pelleting the serum exosomes by ultracentrifugation at 100,000 x g for 2 h at 4°C, and the resulting supernatant was filtered through a 0.2 μm pore filter. Cells were routinely maintained in a humidified chamber at 37°C and 5% CO2.","total RNA","Exosomes were isolated utilizing a combination of centrifugation, ultracentrifugation, and filtration as we have previously described [16] or with the Exoquick-TC reagent (System Biosciences, Mountain View, CA) following the manufacturer’s protocol. For ultracentrifugation isolation, conditioned cell culture media was collected and centrifuged at 10,000 x g for 30 min at 4°C, to remove cells and large debris. The supernatant was filtered using a 0.22-μm pore filter and the exosomes were pelleted at 100,000 x g for 1 h at 4°C. The exosome pellet was washed with 10 ml of 1X PBS and pelleted again by centrifugation at 100,000 x g for 1 h at 4°C. The resulting pellet was either suspended in 1X PBS for whole exosome applications or further processed for RNA or protein extraction. Total RNA was extracted from exosome pellet using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).","Small RNA libraries were constructed using New England Biolabs (NEB) NEBNext Multiplex Small RNA Library Prep Set for Illumina sequencers and the NEB standard protocol. Individual libraries were constructed using 1μg of total RNA isolated from each sample.","9606","Each library was indexed in order to multiplex four samples per sequencing run on the Illumina MiSeq platform using MiSeq 50 cycle Reagent Kits v2. A minimum of 17 million 50bp sequencing reads were collected from each sample and data were analyzed using Genesifter software (formerly Geospiza) (PerkinElmer, Santa Clara CA). Raw data for each sample were aligned to the most recent mirBASE database (mirBase.org [17]) with remaining reads aligned to the most recent human genome (hg18 build [18]) build in order to identify previously unknown regions that may encode for unique miRNAs. Pairwise comparison of the alignment results was done using Genesifter for identification of miRNAs that are differentially expressed at a significant level, i.e. up- or down-regulated.","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN05290414","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1873417","NONE","MCF7","breast cancer"
"GSM2212221","MCF7controlexosome","GSM2212221","Public on Sep 12 2016","Jun 23 2016","May 15 2019","SRA","1","MCF7 breast cancer cells","Homo sapiens","cell line: MCF7","cell type: breast cancer","The human mammary epithelial cell line MCF10A, and breast cancer cell lines MCF7 and MDA-MB-231 were obtained from the American Type Culture Collection (Manassas, VA). MCF10A cells were cultured in DMEM/F12 medium supplemented with 5% exosome-depleted horse serum, 20ng/ml epithelial growth factor, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10 μg/ml insulin, 100 IU/mL penicillin and 100 μg/mL streptomycin. MCF7 and MDA-MB-231 cells were cultivated in DMEM medium supplemented with 10% exosome-depleted fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Exosome-depleted FBS and horse serum were prepared by pelleting the serum exosomes by ultracentrifugation at 100,000 x g for 2 h at 4°C, and the resulting supernatant was filtered through a 0.2 μm pore filter. Cells were routinely maintained in a humidified chamber at 37°C and 5% CO2.","total RNA","Exosomes were isolated utilizing a combination of centrifugation, ultracentrifugation, and filtration as we have previously described [16] or with the Exoquick-TC reagent (System Biosciences, Mountain View, CA) following the manufacturer’s protocol. For ultracentrifugation isolation, conditioned cell culture media was collected and centrifuged at 10,000 x g for 30 min at 4°C, to remove cells and large debris. The supernatant was filtered using a 0.22-μm pore filter and the exosomes were pelleted at 100,000 x g for 1 h at 4°C. The exosome pellet was washed with 10 ml of 1X PBS and pelleted again by centrifugation at 100,000 x g for 1 h at 4°C. The resulting pellet was either suspended in 1X PBS for whole exosome applications or further processed for RNA or protein extraction. Total RNA was extracted from exosome pellet using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).","Small RNA libraries were constructed using New England Biolabs (NEB) NEBNext Multiplex Small RNA Library Prep Set for Illumina sequencers and the NEB standard protocol. Individual libraries were constructed using 1μg of total RNA isolated from each sample.","9606","Each library was indexed in order to multiplex four samples per sequencing run on the Illumina MiSeq platform using MiSeq 50 cycle Reagent Kits v2. A minimum of 17 million 50bp sequencing reads were collected from each sample and data were analyzed using Genesifter software (formerly Geospiza) (PerkinElmer, Santa Clara CA). Raw data for each sample were aligned to the most recent mirBASE database (mirBase.org [17]) with remaining reads aligned to the most recent human genome (hg18 build [18]) build in order to identify previously unknown regions that may encode for unique miRNAs. Pairwise comparison of the alignment results was done using Genesifter for identification of miRNAs that are differentially expressed at a significant level, i.e. up- or down-regulated.","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN05290409","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1873418","NONE","MCF7","breast cancer"
"GSM2212222","MDA-MB-231control-cell","GSM2212222","Public on Sep 12 2016","Jun 23 2016","May 15 2019","SRA","1","MDA-MB-231 breast cancer cells","Homo sapiens","cell line: MDA-MB-231","cell type: breast cancer","The human mammary epithelial cell line MCF10A, and breast cancer cell lines MCF7 and MDA-MB-231 were obtained from the American Type Culture Collection (Manassas, VA). MCF10A cells were cultured in DMEM/F12 medium supplemented with 5% exosome-depleted horse serum, 20ng/ml epithelial growth factor, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10 μg/ml insulin, 100 IU/mL penicillin and 100 μg/mL streptomycin. MCF7 and MDA-MB-231 cells were cultivated in DMEM medium supplemented with 10% exosome-depleted fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Exosome-depleted FBS and horse serum were prepared by pelleting the serum exosomes by ultracentrifugation at 100,000 x g for 2 h at 4°C, and the resulting supernatant was filtered through a 0.2 μm pore filter. Cells were routinely maintained in a humidified chamber at 37°C and 5% CO2.","total RNA","Exosomes were isolated utilizing a combination of centrifugation, ultracentrifugation, and filtration as we have previously described [16] or with the Exoquick-TC reagent (System Biosciences, Mountain View, CA) following the manufacturer’s protocol. For ultracentrifugation isolation, conditioned cell culture media was collected and centrifuged at 10,000 x g for 30 min at 4°C, to remove cells and large debris. The supernatant was filtered using a 0.22-μm pore filter and the exosomes were pelleted at 100,000 x g for 1 h at 4°C. The exosome pellet was washed with 10 ml of 1X PBS and pelleted again by centrifugation at 100,000 x g for 1 h at 4°C. The resulting pellet was either suspended in 1X PBS for whole exosome applications or further processed for RNA or protein extraction. Total RNA was extracted from exosome pellet using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).","Small RNA libraries were constructed using New England Biolabs (NEB) NEBNext Multiplex Small RNA Library Prep Set for Illumina sequencers and the NEB standard protocol. Individual libraries were constructed using 1μg of total RNA isolated from each sample.","9606","Each library was indexed in order to multiplex four samples per sequencing run on the Illumina MiSeq platform using MiSeq 50 cycle Reagent Kits v2. A minimum of 17 million 50bp sequencing reads were collected from each sample and data were analyzed using Genesifter software (formerly Geospiza) (PerkinElmer, Santa Clara CA). Raw data for each sample were aligned to the most recent mirBASE database (mirBase.org [17]) with remaining reads aligned to the most recent human genome (hg18 build [18]) build in order to identify previously unknown regions that may encode for unique miRNAs. Pairwise comparison of the alignment results was done using Genesifter for identification of miRNAs that are differentially expressed at a significant level, i.e. up- or down-regulated.","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN05290410","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1873419","NONE","MDA-MB-231","breast cancer"
"GSM2212223","MDA-MB-231-control-exosome","GSM2212223","Public on Sep 12 2016","Jun 23 2016","May 15 2019","SRA","1","MDA-MB-231 breast cancer cells","Homo sapiens","cell line: MDA-MB-231","cell type: breast cancer","The human mammary epithelial cell line MCF10A, and breast cancer cell lines MCF7 and MDA-MB-231 were obtained from the American Type Culture Collection (Manassas, VA). MCF10A cells were cultured in DMEM/F12 medium supplemented with 5% exosome-depleted horse serum, 20ng/ml epithelial growth factor, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10 μg/ml insulin, 100 IU/mL penicillin and 100 μg/mL streptomycin. MCF7 and MDA-MB-231 cells were cultivated in DMEM medium supplemented with 10% exosome-depleted fetal bovine serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin (Corning/Mediatech, Inc. Manassas, VA). Exosome-depleted FBS and horse serum were prepared by pelleting the serum exosomes by ultracentrifugation at 100,000 x g for 2 h at 4°C, and the resulting supernatant was filtered through a 0.2 μm pore filter. Cells were routinely maintained in a humidified chamber at 37°C and 5% CO2.","total RNA","Exosomes were isolated utilizing a combination of centrifugation, ultracentrifugation, and filtration as we have previously described [16] or with the Exoquick-TC reagent (System Biosciences, Mountain View, CA) following the manufacturer’s protocol. For ultracentrifugation isolation, conditioned cell culture media was collected and centrifuged at 10,000 x g for 30 min at 4°C, to remove cells and large debris. The supernatant was filtered using a 0.22-μm pore filter and the exosomes were pelleted at 100,000 x g for 1 h at 4°C. The exosome pellet was washed with 10 ml of 1X PBS and pelleted again by centrifugation at 100,000 x g for 1 h at 4°C. The resulting pellet was either suspended in 1X PBS for whole exosome applications or further processed for RNA or protein extraction. Total RNA was extracted from exosome pellet using the TRIzol reagent (Invitrogen/Life Technologies) following the manufacturer’s protocol. RNA concentration was quantitated using the NanoDrop ND-100 Spectrophotometer (NanoDrop Technologies, Wilmington, DE).","Small RNA libraries were constructed using New England Biolabs (NEB) NEBNext Multiplex Small RNA Library Prep Set for Illumina sequencers and the NEB standard protocol. Individual libraries were constructed using 1μg of total RNA isolated from each sample.","9606","Each library was indexed in order to multiplex four samples per sequencing run on the Illumina MiSeq platform using MiSeq 50 cycle Reagent Kits v2. A minimum of 17 million 50bp sequencing reads were collected from each sample and data were analyzed using Genesifter software (formerly Geospiza) (PerkinElmer, Santa Clara CA). Raw data for each sample were aligned to the most recent mirBASE database (mirBase.org [17]) with remaining reads aligned to the most recent human genome (hg18 build [18]) build in order to identify previously unknown regions that may encode for unique miRNAs. Pairwise comparison of the alignment results was done using Genesifter for identification of miRNAs that are differentially expressed at a significant level, i.e. up- or down-regulated.","GPL15520","Bethany,,Hannafon","bethany-hannafon@ouhsc.edu","Pathology","University of Oklahoma Health Sciences Center","975 NE 10th Street","Oklahoma city","OK","73104","USA","0","Illumina MiSeq","size fractionation","transcriptomic","miRNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN05290411","SRA: https://www.ncbi.nlm.nih.gov/sra?term=SRX1873420","NONE","MDA-MB-231","breast cancer"
